SELECT Trial: The Evidence for CV Coverage The SELECT trial (published in NEJM, November 2023) demonstrated that Wegovy reduces cardiovascular events: [27] 20% reduction in major adverse cardiovascular events (MACE) Includes heart attacks, strokes, and cardiovascular death 17,604 participants followed for ~3.3 years All participants had established cardiovascular disease plus obesity/overweight Typical Plan Coverage Criteria for CV Indication Medicare plans that cover Wegovy for cardiovascular risk reduction typically require: Clinical Criteria Established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) BMI (body mass index) 27 kg/m No Type 2 diabetes (or T2D not adequately controlled) Concurrent lifestyle modifications (diet and exercise) Required Documentation Cardiology records documenting established CVD Current BMI (height and weight within last 30 days) Letter of Medical Necessity from cardiologist or primary care provider Documentation of lifestyle modification attempts ICD-10 Codes for CV vs
/assets/images/provider/photos/2802570.png)
Scott Pruitt, Mortgage Settlement Holdout, Sell Out His State for Wall Street?"
Moving forward, further research is needed to optimize cold plasma parameters, validate its efficacy across diverse food matrices, and ensure regulatory compliance and consumer acceptance
Supplements that may interact Some researchers combine GLP-1 medications with other weight management supplements
This makes them effective for weight management and reducing stubborn body fat and visceral fat